title: Which individuals undergoing BRACAnalysis need BART testing?
abstract: Deleterious mutations in BRCA1 and BRCA2 include those identified by sequencing technology as well as large genomic rearrangements (LGR). The main testing laboratory in the United States, Myriad Genetics Laboratory (MGL), has defined criteria for inclusion of LGR testing (i.e., BRACAnalysis Rearrangement Test, or BART™) when BRCA1 and BRCA2 testing is ordered. We were interested in determining how many of our patients with LGR mutations in BRCA1 and BRCA2 fulfilled these MGL criteria. A retrospective chart review was performed on all individuals who underwent genetic testing at our institution since August 2006. Individuals who underwent LGR testing were classified as either having or not having a LGR in BRCA1 or BRCA2. Each individual's history was classified as meeting MGL defined LGR criteria, meeting criteria using third-degree relatives, or not meeting criteria. A total of 257 BART tests were ordered at our institution from August 2006 to August 2009. Five individuals (1.9%) had an LGR mutation. Two LGR were identified in patients who met MGL defined LGR criteria. One LGR was identified in a patient that met MGL defined LGR criteria only when using third-degree relatives. Two LGR were identified in individuals who did not meet MGL defined criteria. LGR are present in individuals who do not have a high pretest probability of carrying a mutation in BRCA1 or BRCA2. These data suggest that when BRCA1 and BRCA2 genetic testing is performed, testing should always include LGR testing so that the results are the most comprehensive and reliable.
authors.affiliation: Massachusetts General Hospital, Center for Cancer Risk Assessment, Boston, MA, USA. keshannon@partners.org
authors.forename: Kristen M
authors.initials: KM
authors.lastname: Shannon
authors.forename: Linda H
authors.initials: LH
authors.lastname: Rodgers
authors.forename: Gayun
authors.initials: G
authors.lastname: Chan-Smutko
authors.forename: Devanshi
authors.initials: D
authors.lastname: Patel
authors.forename: Michele
authors.initials: M
authors.lastname: Gabree
authors.forename: Paula D
authors.initials: PD
authors.lastname: Ryan
mesh_terms: D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000517:prevention & control; D003658:Decision Making, Computer-Assisted; D005260:Female; D015321:Gene Rearrangement; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D009154:Mutation / Q000235:genetics*; D011379:Prognosis; D012189:Retrospective Studies; D014481:United States
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human